Beam Therapeutics
| Public company | |
| Traded as | NASDAQ: BEAM |
| ISIN | 🆔US07373V1052 |
| Industry | Biotechnology |
| Founded 📆 | 2017 |
| Founder 👔 | Feng Zhang, David R. Liu, J. Keith Joung, and John Evans |
| Headquarters 🏙️ | Cambridge, United States |
Area served 🗺️ | |
| Members | |
Number of employees | |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
Beam Therapeutics is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby DNA sequences can be modified even more precisely compared to previous methods.[1][2]
History
Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang.[3] Prior to its IPO, the company raised nearly $1 billion in venture capital from investors.[4] In a February 2020 IPO, the company raised $180 million.[5] The first clinical trials for therapies are expected in 2021.[6]
See also
References
- ↑ "Why Beam Therapeutics Climbed 64.5% in June". NASDAQ. Unknown parameter
|url-status=ignored (help) - ↑ Sterling, John (2021-07-15). "Base Editing Shows Promise as Common Inherited Lung and Liver Disease Therapy". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-08-07.
- ↑ Isaacson, Walter (2021). The Code Breaker. Simon & Schuster. pp. 461–462. ISBN 978-1-9821-1585-2. Search this book on
- ↑ Sewell, Dawson; Burns, Joe; Villarisco, Julius John; Faraguna, Carla; Ogolla, Henry; Gomila, Jude; Scherfner, Erin; Hammond, Rebecca; Solanki, Bhupendra. "Beam Therapeutics". Golden. Retrieved 2021-07-08. Unknown parameter
|url-status=ignored (help) - ↑ Dunn, Andrew. "Investors are betting billions that cutting-edge cures can upend how we treat heart disease and transform pharma". Business Insider. Retrieved 2021-08-07.
- ↑ Philippidis, Alex (2020-02-06). "Beam Therapeutics, Base Editing Drug Developer, Raises $180M in IPO". GEN - Genetic Engineering and Biotechnology News. Retrieved 2021-07-08.
This article "Beam Therapeutics" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Beam Therapeutics. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
|
This page exists already on Wikipedia. |
